PATENT CLAIM ANALYSIS

Application Number: 16287559
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["424", "204100"]

Abstract:
The present invention relates to novel CD4+ and CD8+ T cell epitopes that are specific for HPV-specific E6 and E7 oncoproteins, to peptides comprising these novel T cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of HPV related diseases. Preferred epitopes are recognized by a T cell that infiltrates a cervical neoplastic lesion or by a T cell from a draining lymph node, and are presented by an HLA-DQ or HLA-DP molecule, or an HLA-B.

Claim (Index 1):
An immunogenic pharmaceutical composition comprising:\n (a) a peptide having a length of no more than 90 amino acids and comprising at least 31 contiguous amino acids from the amino acid sequence of an HPV E7 protein, wherein the contiguous amino acid sequence comprises SEQ ID NO:17; and (b) an immune-stimulating amount of a pharmaceutically acceptable adjuvant.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 99.0
- Lexical Diversity: 1.57627
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15678970', '14453286', '12451983', '12592815', '11343606']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8270220577666428
- 35 USC 102 Novelty (BERT): 0.6100667824371656
- Combined Prediction Score: 0.805326530233695
- Mean Citation Score: 565.023204
- Max Citation Score: 698.5127
- Similarity Product: 465.2072991961122

Labels:
- Claim Label 101: 0
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test